Please login to the form below

Not currently logged in

ICER to review the role of health insurers in determining patient access to prescription drugs

Non-profit research institute will evaluate how health insurance policies may harm patient access to treatment

The Institute for Clinical and Economic Review (ICER) is set to review how health insurers’ prescription drug policies affect patient access in the US, the independent non-profit research institute announced yesterday.

The first annual assessment into how health insurance policies may harm patient access to treatment will seek input from patient advocates, clinician speciality societies, US payers and life sciences companies.

According to the assessment protocol: 'The overall objective of the assessment is to test whether the fair access criteria can help bring greater transparency to the public debates about fair insurance coverage for drugs and, in addition, promote the positive linkage of fair pricing with fair access that will advance the best interests of patients and the health system.'

ICER will aim to determine how well the insurance policies align with its set of fair access standards. As part of the first iteration of the annual assessment, ICER will use MMIT’s market access analytics solution to evaluate the coverage policies of 15 of the largest commercial payers in the US.

To determine if the coverage policies match its criteria for fair patient access, ICER will examine tiering, step therapy requirements and elements of the prior authorisation criteria for 28 drugs.

These 28 specific drugs will have been previously found by ICER to be priced fairly and at a cost-effective level.

The review follows previous research undertaken by ICER that analysed the ethical and practical elements of insurance coverage policy in the US.

The white paper, published in September 2020, presented a set of criteria that will support a ‘more transparent’ discussion among healthcare stakeholders to  identify if specific policies are delivering fair patient access to prescription medications.

Following this, ICER convened a multi-stakeholder working group to advise on the new annual assessment initiative, to aid in its efforts to evaluate ‘barriers to access’ in prescription drug coverage policies of US payers.

In a statement, ICER said that it expects to publish its first annual assessment of these access barriers on 20 October 2021.

Article by
Lucy Parsons

26th May 2021

From: Research, Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...